Abstract: A pharmaceutical composition for eardrum repair includes: collagen present in an amount of 8 wt % to 12 wt %; a forming agent present in an amount of 19 wt % to 22 wt %; and rest of a solvent, wherein the forming agent is a polymer of polyethylene oxide (PEO) and polypropylene oxide (PPO), polystyrene, polyethylene, polypropylene, polymethylmethacrylate, poly(N-isopropylacrylamide), poly[2-(dimethylamino)ethyl methacrylate] (pDMAEMA) hydroxypropylcellulose, poly(vinylcaprolactame), poly-2-isopropyl-2-oxazoline, polyvinyl methyl ether or a combination thereof.

Abstract: A probe for monitoring new bone formation and osseointegration containing an integrin ?5?1 ligand conjugated to a near-infrared fluorescent dye in which the integrin ?5?1 ligand is a cyclic peptide lacking an RGD sequence. Also disclosed is a bone repair and osteogenesis-monitoring probe formed of a bisphosphonate conjugated to a gold nanoparticle, the probe having a size of 1 nm to 10 nm. Further disclosed are two methods for monitoring bone formation, each of which is carried out by administering the above probes and obtaining a near-infrared fluorescence image.

Abstract: The invention discloses a method of accelerating osteogenic differentiation and a composition thereof. The method comprises a step of adding type II collagen into stem/progenitor cells or osteoblasts to accelerate the osteogenic differentiation of the added cells, and the composition comprises type II collagen, and stem/progenitor cells or osteoblasts. Type II collagen can accelerate osteogenesis of mesenchymal stem cells (MSCs) much faster than does type I collagen. The said composition is effective to facilitate bone repair upon introduction of the composition into various osseous defects.

Abstract: The present invention provides a method for restoring native chondrocyte phenotype and functions of, and/or increasing type II collagen as well as aggrecan mRNA expression levels and GAG accumulation level in dedifferentiated chondrocytes which have been subcultured and expanded in vitro, which comprising culturing the said dedifferentiated chondrocytes in vitro with a medium comprising type II collagen, or its biologically active peptide fragment(s) or analogs with or without growth factor(s), wherein the type II collagen or its biologically active peptide fragment(s) or analogs are effective to restore chondrocyte phenotype and functions of, and/or to increase type II collagen and aggrecan expression levels and GAG accumulation level in the said dedifferentiated chondrocytes.

Abstract: The invention discloses a bone implant and a manufacturing method thereof. The manufacturing method of the bone implant comprises a step of coating or mixing type II collagen with at least one porous bone material comprising metals, bio-ceramics, natural biopolymers and synthetic polymers. Another manufacturing method of the bone implant comprises the steps of loading type II collagen with or without at least one porous bone material in a container, and lyophilizing the type II collagen to generate a type II collagen sponge construct with or without the porous bone material as the bone material. The manufactured bone implants are effective, with or without loading cells having differentiation tendency towards osteogenesis, to facilitate bone repair upon introduction of the bone implant into various osseous defects.

Abstract: The invention discloses a method of accelerating osteogenic differentiation and a composition thereof. The method comprises a step of adding type II collagen into stem/progenitor cells or osteoblasts to accelerate the osteogenic differentiation of the added cells, and the composition comprises type II collagen, and stem/progenitor cells or osteoblasts. Type II collagen can accelerate osteogenesis of mesenchymal stem cells (MSCs) much faster than does type I collagen. The said composition is effective to facilitate bone repair upon introduction of the composition into various osseous defects.

Abstract: The present invention provides a method for restoring native chondrocyte phenotype and functions of, and/or increasing type II collagen as well as aggrecan mRNA expression levels and GAG accumulation level in dedifferentiated chondrocytes which have been subcultured and expanded in vitro, which comprising culturing the said dedifferentiated chondrocytes in vitro with a medium comprising type II collagen, or its biologically active peptide fragment(s) or analogs with or without growth factor(s), wherein the type II collagen or its biologically active peptide fragment(s) or analogs are effective to restore chondrocyte phenotype and functions of, and/or to increase type II collagen and aggrecan expression levels and GAG accumulation level in the said dedifferentiated chondrocytes.